Squarepoint Ops LLC Buys 53,948 Shares of Jounce Therapeutics Inc (JNCE)
Squarepoint Ops LLC lifted its stake in Jounce Therapeutics Inc (NASDAQ:JNCE) by 239.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 76,457 shares of the company’s stock after acquiring an additional 53,948 shares during the period. Squarepoint Ops LLC owned 0.23% of Jounce Therapeutics worth $258,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rhumbline Advisers raised its position in shares of Jounce Therapeutics by 39.4% in the 4th quarter. Rhumbline Advisers now owns 19,151 shares of the company’s stock worth $65,000 after acquiring an additional 5,410 shares in the last quarter. Bank of America Corp DE increased its position in Jounce Therapeutics by 37.4% during the 4th quarter. Bank of America Corp DE now owns 35,082 shares of the company’s stock valued at $118,000 after buying an additional 9,544 shares in the last quarter. SG Americas Securities LLC acquired a new position in Jounce Therapeutics during the 4th quarter valued at about $55,000. Geode Capital Management LLC increased its position in Jounce Therapeutics by 14.7% during the 4th quarter. Geode Capital Management LLC now owns 161,421 shares of the company’s stock valued at $543,000 after buying an additional 20,638 shares in the last quarter. Finally, Raymond James & Associates acquired a new position in Jounce Therapeutics during the 4th quarter valued at about $71,000. 72.65% of the stock is owned by hedge funds and other institutional investors.
Several research analysts recently issued reports on JNCE shares. JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Jounce Therapeutics in a research report on Thursday, March 7th. Zacks Investment Research lowered Jounce Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 16th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the company. Jounce Therapeutics currently has an average rating of “Hold” and an average target price of $11.67.
Jounce Therapeutics (NASDAQ:JNCE) last announced its earnings results on Wednesday, March 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.35) by $0.29. Jounce Therapeutics had a negative return on equity of 25.69% and a negative net margin of 41.99%. The company had revenue of $20.10 million for the quarter, compared to analyst estimates of $12.86 million. As a group, equities research analysts anticipate that Jounce Therapeutics Inc will post -1.2 earnings per share for the current year.
About Jounce Therapeutics
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Featured Story: Purposes and Functions of the Federal Reserve
Want to see what other hedge funds are holding JNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jounce Therapeutics Inc (NASDAQ:JNCE).
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.